67 source-backed listings mapped to this modality. Use each profile to verify FDA file number, workflow fit, integration, deployment, and unknown fields.
Turn this list into an evaluation
Each entry is an FDA submission, not a distinct commercial offer. Inspect the exact record before comparing evidence, asking for a quote or planning an integration.
Which acquisition protocols and input series match the exact labeled scope?
Is the proposed job detection, reading support, quantification, processing or another role?
How will outputs reach the reader, and who will test the installed configuration?
Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.
Authorized purpose: BAC processes screening FFDM and DBT mammograms to detect the presence or absence of breast arterial calcifications at study and breast level and localize detected calcifications for qualified interpreting-physician review.
Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.
Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems, marking soft-tissue lesions and calcifications with abnormality scores.
Authorized purpose: Prioritizes suspicious screening DBT examinations for MQSA interpreting physicians; every examination remains subject to full physician review.
PMA supplement updates digital breast tomosynthesis reconstruction with deep learning to correct sparse-view artifacts, compensate patient motion, and enhance soft-tissue lesion visibility in the synthetic 2D image.
Authorized purpose: MammoScreen BD evaluates 2D mammography standard views (CC and/or MLO) from compatible FFDM and/or 2D synthetic mammography from DBT to assign an ACR BI-RADS 5th Edition breast-density category for asymptomatic women aged 40 years or older undergoing screening; it is adjunctive, not diagnostic, and patient management remains with the interpreting physician.
Authorized purpose: Saige-Dx analyzes screening DBT stacks and associated full-field digital or synthetic 2D mammograms, assigning finding and case suspicion levels to support qualified interpreting physicians; it does not replace their review or clinical judgment.
Authorized purpose: Genius AI Detection 2.0 analyzes compatible digital breast tomosynthesis exams to identify and mark soft-tissue densities (masses, architectural distortions, asymmetries) and calcifications, providing lesion location/outline, confidence or Certainty of Findings, and a case score for concurrent review; the interpreting physician confirms or dismisses findings.
Authorized purpose: Identifies calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; it is not a standalone diagnostic device.
Authorized purpose: Allix5 generates a five-year breast-cancer-risk prediction from bilateral screening mammograms for eligible patients without known breast cancer at presentation; it is not intended to diagnose or detect cancer, recommend care, or serve as the sole determinant of care.
Authorized purpose: cmAngio (V1.6) processes screening mammograms to aid a qualified interpreting physician in the manual process of identifying breast arterial calcification. It detects the presence or absence of breast arterial calcifications at the study and breast level in full-field digital mammography and digital breast tomosynthesis screening mammograms and marks BAC segments on image thumbnails for localization.
Authorized purpose: Concurrent reading aid for qualified interpreting physicians on screening DBT mammograms to identify soft-tissue lesions and calcifications that may indicate cancer and assign finding- and case-level suspicion.
Authorized purpose: Transpara 2.1.0 is a concurrent reading aid for physicians interpreting screening full-field digital mammography and digital breast tomosynthesis, providing region and examination scores to support review of suspicious breast findings.
Modality
Mammography/DBT
Anatomy
Breast; regions suspicious for cancer on screening mammography and digital breast tomosynthesis
Authorized purpose: Concurrent reading aid for interpreting physicians on screening DBT mammograms to detect and characterize soft-tissue lesions and calcifications that may indicate cancer.
Authorized purpose: Concurrent CAD/CADx aid for interpreting physicians reading compatible DBT exams to detect soft-tissue densities and calcifications for physician confirmation or dismissal.
Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems.
Authorized purpose: Adjunctively assess breast tissue composition and provide an ACR BI-RADS 5th Edition breast-density category for asymptomatic women aged 40 years or older undergoing screening mammography; it is not diagnostic.
The FDA PMA supplement record identifies MAMMOMAT B.brilliant with Tomosynthesis Option as digital breast tomosynthesis and approves a new PREMIA reconstruction algorithm, updated image-acquisition hardware enabling a faster tomosynthesis scan, and rebranding of the system. The FDA product-classification text states that the device generates digital three-dimensional mammographic images for breast-cancer screening and diagnosis.
Authorized purpose: Concurrent reading and reporting aid for physicians interpreting screening mammograms on compatible full-field digital mammography and digital breast tomosynthesis systems, optionally using compatible prior examinations; outputs are adjunctive and must not be the sole basis for patient-management decisions.
The VinDr-Mammo is a passive notification for prioritization-only, a parallel- workflow software tool used by MQSA qualified interpreting physicians to prioritize patients with suspicious findings in the medical care environment. VinDr-Mammo utilizes an artificial intelligence algorithm to analyze 2D FFDM screening mammograms and flags those that are suggestive of the presence of at least one suspicious finding at the exam- level. VinDr-Mammo produces an exam-level output to a PACS/Workstation for flagging the suspicious case and allows worklist prioritization. MQSA qualified interpreting physicians are responsible for reviewing each exam on a display approved for use in mammography, according to the current standard of care. VinDr-Mammo device is limited to the categorization of exams, does not provide any diagnostic information beyond triage and prioritization, does not remove images from the interpreting physician’s worklist, and should not be used in lieu of full patient evaluation, or relied upon to make or confirm diagnosis. The VinDr-Mammo device is intended for use with complete 2D FFDM mammography exams acquired using validated FFDM systems only.
Authorized purpose: Automatically determine volumetric breast density, breast volume, and an ACR BI-RADS 5th Edition breast-density category from compatible digital mammography and digital breast tomosynthesis data to aid healthcare professionals in assessing breast tissue composition; it is not a diagnostic aid.
Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize suspected breast-cancer lesions in screening DBT exams from compatible systems.
Authorized purpose: cmAngio processes screening FFDM and DBT mammograms to detect presence or absence of breast arterial calcifications at study and breast level and mark segments for qualified interpreting-physician review; it is not primary breast-cancer interpretation or a standalone diagnostic or treatment decision tool.
Authorized purpose: Provides CADe/CADx for compatible DBT examinations by marking breast masses, distortions/asymmetries, and calcifications for concurrent physician interpretation.
Authorized purpose: Provides a softcopy review environment for screening and diagnostic digital breast tomosynthesis, including visualization and image-enhancement aids.
Authorized purpose: Provides an adjunctive BI-RADS 5th Edition breast-density category to aid assessment of breast tissue composition; it is not a diagnostic aid.
Authorized purpose: Genius AI Detection 2.0 analyzes compatible digital breast tomosynthesis images to identify and mark soft-tissue densities and calcifications with confidence scores and case scoring for concurrent physician interpretation.
Modality
Mammography/DBT
Anatomy
Breast; soft-tissue densities, architectural distortions or asymmetries, and calcifications
Authorized purpose: Concurrent reading aid for physicians interpreting screening FFDM/DBT to identify suspicious breast regions and estimate malignancy likelihood.
Authorized purpose: Assist trained interpreting physicians in analyzing breast-ultrasound images of patients with soft-tissue breast lesions suspicious for cancer who are referred for further diagnostic ultrasound examination.
Authorized purpose: Concurrent reading aid for interpreting physicians reading screening FFDM or DBT, to identify findings and assess suspicion; it is not the sole basis for management.
Authorized purpose: Aid interpreting physicians in detecting, localizing, and characterizing suspicious breast-cancer areas on mammograms from compatible FFDM systems, viewed after the physician completes the initial read.
Authorized purpose: Calculation of percent breast density and breast-density group information (BI-RADS A+B fatty versus C+D dense) as adjunctive information for interpreting physicians assessing breast tissue composition; not a diagnostic aid.
Modality
Mammography/DBT
Anatomy
Breast tissue, including fibroglandular tissue and total breast area, assessed for each breast.
Authorized purpose: Visualization, analysis, reporting, lesion measurement, kinetic assessment, and MR-guided breast interventional planning; when interpreted by a skilled physician, information may support screening, diagnosis, and intervention planning, but patient management must not rely solely on the results.
Modality
Mammography/DBT
Anatomy
Breast lesions and breast morphological landmarks including nipple, chest, and skin borders.
Authorized purpose: Provides volumetric breast density, BI-RADS fourth- or fifth-edition density categories and dose/pressure quality metrics from raw mammography or DBT data as adjunctive information for an MQSA-qualified physician's breast-composition assessment.
Authorized purpose: Provide a breast-density category from synthetic 2D images generated from DBT to aid assessment of breast tissue composition; the output is adjunctive and not a diagnostic aid.
Authorized purpose: Concurrent reading aid for physicians interpreting screening FFDM and DBT to identify suspicious regions and assess malignancy likelihood.
Authorized purpose: Concurrent or secondary CAD assistance to interpreting physicians for detection, localization, and characterization of soft-tissue densities (masses, architectural distortions, and asymmetries) and calcifications; not a primary read.
Modality
Mammography/DBT
Anatomy
Breast, including soft-tissue densities and calcifications in 3D DBT slices.
Authorized purpose: Genius AI Detection analyzes compatible digital breast tomosynthesis images to identify and mark soft-tissue densities and calcifications with confidence scores and case scoring for concurrent physician interpretation.
Modality
Mammography/DBT
Anatomy
Breast; soft-tissue densities and calcifications in digital breast tomosynthesis
Authorized purpose: MammoScreen is a concurrent reading aid for interpreting physicians reviewing screening full-field digital mammography; it marks suspicious soft-tissue lesions and calcifications and provides suspicion scores, while patient management is not based solely on the device.
Authorized purpose: Transpara version 1.6 is a concurrent screening aid for FFDM and DBT that presents suspicious-region marks, region scores from 0 to 100, and an exam score from 1 to 10 for physician review.
Authorized purpose: Provides an ACR BI-RADS 5th Edition breast-density category from compatible full-field digital mammography and DBT as adjunctive information, not a diagnostic aid.
Authorized purpose: Transpara version 1.5 is a concurrent screening full-field digital mammography aid that presents suspicious-region marks and scores for physician review and cannot be used as the sole basis for interpretation.
Authorized purpose: Adjunctive breast-cancer decision support during diagnostic ultrasound for patients referred for further diagnostic ultrasound; classifies a user-selected lesion ROI into four BI-RADS-aligned categories and assesses shape and orientation.
Authorized purpose: Passive, prioritization-only notification of 2D FFDM screening mammograms with at least one suspicious finding at the exam level; not diagnostic.
Authorized purpose: Transpara is a concurrent reading aid for screening mammograms that marks suspicious regions, lesions, and calcifications and provides malignancy scores for qualified physician review; patient management is not based solely on the device.
Authorized purpose: Volpara Imaging Software processes raw digital breast X-ray and tomosynthesis data to calculate breast-density maps, volumetric density, and a BI-RADS density category as an adjunct to qualified physician interpretation.
Authorized purpose: Adjunctive estimation of the BI-RADS 5th Edition breast-density category from processed digital 2D mammograms to aid radiologists; not diagnostic.
DM-Density is a software application intended for use with compatible full field digital mammography systems. DMDensity calculates percent breast density defined as the ratio of fibroglandular tissue to total breast area estimates. DM-Density provides these numerical values for each breast as well as a density category to aid interpreting physicians in the assessment of breast tissue composition. DM-Density produces adjunctive information. It is not a diagnostic aid.
Authorized purpose: Quantra 2.2 analyzes digital breast X-ray images and categorizes breast density to provide additional information for a radiologist's assessment.
Concurrent computer-aided detection for radiologists interpreting compatible GE Senoclaire breast tomosynthesis examinations, with detected soft-tissue densities blended into the synthetic two-dimensional mammography image.
Authorized purpose: Volpara processes raw data from digital breast x-ray systems, including tomosynthesis, to calculate density maps, volumetric breast density, and BI-RADS breast-density categories as adjunctive information for an MQSA-qualified interpreting physician.
Authorized purpose: Quantra version 2.1 calculates volumetric and area breast-density measures and density categories from supported digital mammography images as an adjunct, not a diagnostic result.
Authorized purpose: Quantra version 1.1 calculates a volumetric breast-density ratio from supported Hologic full-field digital mammography images on the Cenova server as an adjunct, not a diagnostic result.
Authorized purpose: The Second Look computer-aided detection system for mammography is intended to identify and mark regions of interest on standard mammographic views after the initial reading has been completed, bringing them to the radiologist's attention and helping minimize observational oversights by identifying areas that may warrant a second review.
Authorized purpose: The ImageChecker M1000 is a computer system intended to identify and mark regions of interest on routine screening mammograms after the initial reading has been completed, bringing them to the radiologist's attention and helping minimize observational oversights by identifying areas that may warrant a second review.